Spain establishes "voluntary" centralised medtech purchasing
This article was originally published in Clinica
Executive Summary
This week's passage in Spain of law 8/2010 on the reduction of the public deficit will see the creation of a national centralised healthcare products purchasing system. The move had been agreed unanimously by the inter-territorial council of the national health system (of central and regional governments) on 18 March 2010. Adoption of the system on the part of the regional authorities is voluntary, said the health ministry in a statement. However, the health ministry described the decision to centralise purchasing as "one of the most important taken [during the 18 March meeting] for making the national health system more efficient and sustainable".
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.